Supplemental beta-carotene, smoking, and urinary F2-isoprostane excretion in patients with prior early stage head and neck cancer.
Mayne
Susan T
ST
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA. Susan.Mayne@Yale.Edu
Walter
Mary
M
Cartmel
Brenda
B
Goodwin
W Jarrard
WJ
Blumberg
Jeffrey
J
D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage* / Q000627:therapeutic use; D019587:Dietary Supplements; D004311:Double-Blind Method; D028441:F2-Isoprostanes / Q000652:urine*; D008401:Gas Chromatography-Mass Spectrometry; D006258:Head and Neck Neoplasms / Q000517:prevention & control* / Q000652:urine; D006801:Humans; D015227:Lipid Peroxidation; D008137:Longitudinal Studies; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D016609:Neoplasms, Second Primary / Q000517:prevention & control* / Q000652:urine; D010919:Placebos; D012907:Smoking; D019207:beta Carotene / Q000008:administration & dosage* / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D000975:Antioxidants; D028441:F2-Isoprostanes; D010919:Placebos; D019207:beta Carotene